Disappointing interim results from a Phase III trial of its lead cancer drug, Canvaxin, prompted CancerVax Corp. to stop development of the drug and downsize the company's work force by more than half. (BioWorld Today)
Disappointing interim results from a Phase III trial of its lead cancer drug, Canvaxin, prompted CancerVax Corp. to stop development of the drug and downsize the company's work force by more than half. (BioWorld Today)
Shares of ConjuChem Inc. plunged more than 50 percent after the company said it was temporarily stopping development of its DAC:GLP-1 compound in favor of a preclinical candidate that promises longer-term dosing to stabilize glucose levels in Type II diabetics. (BioWorld Today)
